This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Epocrates Helped Physicians Avoid 27 Million Drug Errors In 2012

Stocks in this article: EPOC

SAN MATEO, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- Patient safety is a top priority for all clinicians, yet preventable drug errors are still prevalent throughout the United States. In the past year, Epocrates (Nasdaq:EPOC) has helped clinicians avoid more than 27 million adverse drug events through its popular medical application. This translates to more than 25 percent of Epocrates drug lookups preventing a minor to serious adverse drug event.

Sixty percent of U.S. physicians who use the Epocrates app reported avoiding at least one adverse drug error every week through the company's mobile and online reference products, according to a recent survey 1. Physicians cite the drug Interaction Checker as the most helpful safety feature in the Epocrates app and a primary influence in changing prescribing decisions. The Interaction Checker enables clinicians to quickly enter up to 30 prescription, over-the-counter and alternative medicines to view potential interactions in order of severity. Additional safety features in the app include drug dosing, adverse reactions and news alerts.

"Epocrates delivers invaluable information at my fingertips with access to prescribing information when and where I need it," said Dr. W. Wolfe, Spotsylvania, Va. "The product has made my treatment of patients safer. I would find it more difficult to practice medicine without Epocrates, given the increasing complexities of medicine."

With drug information changing at a rapid pace, it is important for physicians to have information readily available at the point of care. In 2012, the Food and Drug Administration (FDA) approved 35 new prescription medications, one of the highest authorization levels in history. As more drugs join the market, new indications are approved and the average patient is taking multiple medications, physicians need easy access to trusted medication safety information instantly.

"Epocrates is a very valuable tool for me as someone with chronic illness on multiple medications. I need to closely monitor for potential interactions with my physician and can immediately review results together on a smartphone," said John Chaney, Pikeville, Ky.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs